Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)

Completed · Phase 3 · Has a placebo group

Conditions studied: Postmenopausal Symptoms

In brief

The purpose of this study is to assess the safety \& efficacy of Brisdelle (paroxetine mesylate) Capsules 7.5 mg for treatment of vasomotor symptoms (VMS) associated with menopause.

Key facts

Study ID
NCT01361308
Run by
Noven Therapeutics
People needed
614
Starts
2011-05-01
Expected to finish
2012-02-01
Last updated by the study team
2015-10-15

Who can join

Age: 40 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.